Bavarian Nordic GMBH
Hørsholm, , DK
Large Business (>100M TTM Revenue)
Bavarian Nordic focuses on developing product candidates to address cancer and infectious diseases by leveraging several core strengths:
Revenue generating; consistent break even results
Fully integrated R&D & manufacturing
Two major pharma collaborations
Differentiated pipeline in infectious diseases and oncology
Approved discovery platform
Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its partner Janssen are developing an Ebola vaccine regimen, which has been fast-tracked, with the backing of worldwide health authorities, and a vaccine for the prevention and treatment of HPV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC.
|Bavarian Nordic GMBH Agern Alle 1 Hørsholm, , DK-2970 Denmark|
|Bavarian Nordic GMBH 1 Agern Alle Hørsholm, , 2970 Denmark|
|Bavarian Nordic GMBH 13 Fraunhoferstraße Planegg, BY, 82152 Germany|
|Bavarian Nordic GMBH 595 Penobscot Drive Redwood City, CA, 94063 United States|
|Bavarian Nordic GMBH 2900 Fire Tower Road Ijamsville, MD, 21754 United States|
To request access, simply fill out the form below and we will contact you.